Table 3 Summary of clinical trials investigating the combination of ADCs and endocrine therapy
From: The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Target | NCT number | Other names | Drug | Partner drugs | Partner drug category | Phase | Start | Treatment setting | Efficacy |
|---|---|---|---|---|---|---|---|---|---|
HER2 | NCT01772472 [30] | KATHERINE | T-DM1 | Unspecified | ET | III | 2013 | Adjuvant, BC | Positive |
NCT04556773 (active, not recruiting) | DB-08 | T-DXd | Anastrozole or Fulvestrant | ET | Ib | 2020 | mBC | NA | |
NCT04553770 [31] | NA | T-DXd | Anastrozole | ET | II | 2020 | Neoadjuvant, BC | NA | |
HER3 | NCT05569811Â (active, not recruiting) | VALENTINE | Patritumab deruxtecan | Letrozole | ET | II | 2022 | Neoadjuvant, BC | NA |